SEC INSIDER TRANSACTIONS

Merck & Co., Inc. (MRK) Insider Transactions

Explore official ownership filings, with every record linked to its source.

Reported data · not live

MRK · Merck & Co., Inc.

Filing window SEC codes (comma separated) Security type Order

More transaction filters

Roles: director,officer,ten_percent_owner,otherOwner nameOfficer titleOwnership: D, I, unknownoriginal or amendedTransaction fromTransaction throughFiled fromFiled throughMinimum quantityMaximum quantityMinimum priceMaximum priceMinimum calculated valueMaximum calculated valueResults per page (1–100)

OR within codes/roles; AND between categories. Roles apply to buyers and sellers. Owner predicates match the same owner. Missing values fail numeric/date filters. Value is quantity × reported price for non-derivative rows only; derivative values are unknown. Amendments stay separate; joint owners do not duplicate rows.

Reset filters

Active filters: days=6m

Stale snapshot · Covered: filings 2026-05-14 to 2026-11-13 · 29 filings · fetched 2026-11-13T18:57:54Z

Recent reported activity

0purchase rows on this page

4sale rows on this page

52matching filing rows

Purchases and sales count original non-derivative P and S rows. Awards, gifts, exercises, derivatives and amendments are shown separately and are not described as market purchases.

Transaction / filed	Reporting owner(s)	Code / security	Quantity	Price as filed	Ownership	Source
2026-08-05Filed 2026-08-07	Maraldo David R.Officer · EVP & Pres. MMD Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.6400 to $128.8500, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in the footnote. F2 The option vested and became exercisable in three equal installments on 5/4/2022, 5/4/2023, and 5/4/2024. F3 The option vested and become exercisable in three equal installments on 5/3/2023, 5/3/2024, and 5/3/2025. F4 The options vest and become exercisable in three equal installments on 4/29/2026, 4/29/2027, and 4/29/2028. References:	M Exercise / conversionCommon Stock · Non-derivative	9,709A	87.1	Direct	Form 4 ↗0000310158-26-000215
2026-08-05Filed 2026-08-07	Maraldo David R.Officer · EVP & Pres. MMD Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.6400 to $128.8500, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in the footnote. F2 The option vested and became exercisable in three equal installments on 5/4/2022, 5/4/2023, and 5/4/2024. F3 The option vested and become exercisable in three equal installments on 5/3/2023, 5/3/2024, and 5/3/2025. F4 The options vest and become exercisable in three equal installments on 4/29/2026, 4/29/2027, and 4/29/2028. References: F1	S Sale (market/private)Common Stock · Non-derivative	6,311D	128.7179	Direct	Form 4 ↗0000310158-26-000215
2026-08-05Filed 2026-08-07	Maraldo David R.Officer · EVP & Pres. MMD Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.6400 to $128.8500, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in the footnote. F2 The option vested and became exercisable in three equal installments on 5/4/2022, 5/4/2023, and 5/4/2024. F3 The option vested and become exercisable in three equal installments on 5/3/2023, 5/3/2024, and 5/3/2025. F4 The options vest and become exercisable in three equal installments on 4/29/2026, 4/29/2027, and 4/29/2028. References:	M Exercise / conversionCommon Stock · Non-derivative	6,311A	73.73	Direct	Form 4 ↗0000310158-26-000215
2026-08-05Filed 2026-08-07	Williams David MichaelOfficer · EVP,Chief Info&Digital Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.7050 to $128.9700, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F2 The option vested and became exercisable in three equal installments on 5/3/2020, 5/3/2021, and 5/3/2022. F3 Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. F4 The option vested and became exercisable in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023. F5 The option vested and became exercisable in three equal installments on 5/4/2022, 5/4/2023, and 5/4/2024. References: F3, F5	M Exercise / conversionStock Option (Right to Buy) · Derivative	34,705D	0	Direct	Form 4 ↗0000310158-26-000214
2026-08-05Filed 2026-08-07	Williams David MichaelOfficer · EVP,Chief Info&Digital Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.7050 to $128.9700, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F2 The option vested and became exercisable in three equal installments on 5/3/2020, 5/3/2021, and 5/3/2022. F3 Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. F4 The option vested and became exercisable in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023. F5 The option vested and became exercisable in three equal installments on 5/4/2022, 5/4/2023, and 5/4/2024. References: F3, F4	M Exercise / conversionStock Option (Right to Buy) · Derivative	13,542D	0	Direct	Form 4 ↗0000310158-26-000214
2026-08-05Filed 2026-08-07	Williams David MichaelOfficer · EVP,Chief Info&Digital Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.7050 to $128.9700, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F2 The option vested and became exercisable in three equal installments on 5/3/2020, 5/3/2021, and 5/3/2022. F3 Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. F4 The option vested and became exercisable in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023. F5 The option vested and became exercisable in three equal installments on 5/4/2022, 5/4/2023, and 5/4/2024. References: F2	M Exercise / conversionStock Option (Right to Buy) · Derivative	4,600D	0	Direct	Form 4 ↗0000310158-26-000214
2026-08-05Filed 2026-08-07	Williams David MichaelOfficer · EVP,Chief Info&Digital Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.7050 to $128.9700, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F2 The option vested and became exercisable in three equal installments on 5/3/2020, 5/3/2021, and 5/3/2022. F3 Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. F4 The option vested and became exercisable in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023. F5 The option vested and became exercisable in three equal installments on 5/4/2022, 5/4/2023, and 5/4/2024. References: F1	S Sale (market/private)Common Stock · Non-derivative	34,705D	128.7707	Direct	Form 4 ↗0000310158-26-000214
2026-08-05Filed 2026-08-07	Williams David MichaelOfficer · EVP,Chief Info&Digital Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.7050 to $128.9700, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F2 The option vested and became exercisable in three equal installments on 5/3/2020, 5/3/2021, and 5/3/2022. F3 Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. F4 The option vested and became exercisable in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023. F5 The option vested and became exercisable in three equal installments on 5/4/2022, 5/4/2023, and 5/4/2024. References:	M Exercise / conversionCommon Stock · Non-derivative	34,705A	73.73	Direct	Form 4 ↗0000310158-26-000214
2026-08-05Filed 2026-08-07	Williams David MichaelOfficer · EVP,Chief Info&Digital Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.7050 to $128.9700, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F2 The option vested and became exercisable in three equal installments on 5/3/2020, 5/3/2021, and 5/3/2022. F3 Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. F4 The option vested and became exercisable in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023. F5 The option vested and became exercisable in three equal installments on 5/4/2022, 5/4/2023, and 5/4/2024. References: F1	S Sale (market/private)Common Stock · Non-derivative	13,542D	128.7707	Direct	Form 4 ↗0000310158-26-000214
2026-08-05Filed 2026-08-07	Williams David MichaelOfficer · EVP,Chief Info&Digital Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.7050 to $128.9700, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F2 The option vested and became exercisable in three equal installments on 5/3/2020, 5/3/2021, and 5/3/2022. F3 Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. F4 The option vested and became exercisable in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023. F5 The option vested and became exercisable in three equal installments on 5/4/2022, 5/4/2023, and 5/4/2024. References:	M Exercise / conversionCommon Stock · Non-derivative	13,542A	75.36	Direct	Form 4 ↗0000310158-26-000214
2026-08-05Filed 2026-08-07	Williams David MichaelOfficer · EVP,Chief Info&Digital Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.7050 to $128.9700, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F2 The option vested and became exercisable in three equal installments on 5/3/2020, 5/3/2021, and 5/3/2022. F3 Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. F4 The option vested and became exercisable in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023. F5 The option vested and became exercisable in three equal installments on 5/4/2022, 5/4/2023, and 5/4/2024. References: F1	S Sale (market/private)Common Stock · Non-derivative	4,600D	128.7707	Direct	Form 4 ↗0000310158-26-000214
2026-08-05Filed 2026-08-07	Williams David MichaelOfficer · EVP,Chief Info&Digital Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.7050 to $128.9700, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F2 The option vested and became exercisable in three equal installments on 5/3/2020, 5/3/2021, and 5/3/2022. F3 Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. F4 The option vested and became exercisable in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023. F5 The option vested and became exercisable in three equal installments on 5/4/2022, 5/4/2023, and 5/4/2024. References:	M Exercise / conversionCommon Stock · Non-derivative	4,600A	77.62	Direct	Form 4 ↗0000310158-26-000214
2026-06-30Filed 2026-07-01	Seidman Christine EDirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 1-for-1 F2 Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. References: F1, F2	A Award / grantPhantom Stock · Derivative	63.2296A	128.5	Direct	Form 4 ↗0000310158-26-000202
2026-06-30Filed 2026-07-01	Karsanbhai Surendralal LancaDirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 1-for-1 F2 Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. References: F1, F2	A Award / grantPhantom Stock · Derivative	126.4591A	128.5	Direct	Form 4 ↗0000310158-26-000200
2026-06-30Filed 2026-07-01	Coe Mary EllenDirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 1-for-1 F2 Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. References: F1, F2	A Award / grantPhantom Stock · Derivative	233.463A	128.5	Direct	Form 4 ↗0000310158-26-000198
2026-05-29Filed 2026-06-02	Warden Kathy JDirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 1-for-1 F2 Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 Holdings include shares acquired in dividend reinvestment transactions. References: F1, F2, F3	A Award / grantPhantom Stock · Derivative	1,853.0997A	118.72	Direct	Form 4 ↗0000310158-26-000177
2026-05-29Filed 2026-06-02	Karsanbhai Surendralal LancaDirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 1-for-1 F2 Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 Holdings include shares acquired in dividend reinvestment transactions. References: F1, F2, F3	A Award / grantPhantom Stock · Derivative	1,853.0997A	118.72	Direct	Form 4 ↗0000310158-26-000171
2026-05-29Filed 2026-06-02	Coe Mary EllenDirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 1-for-1 F2 Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 Holdings include shares acquired in dividend reinvestment transactions. References: F1, F2, F3	A Award / grantPhantom Stock · Derivative	1,853.0997A	118.72	Direct	Form 4 ↗0000310158-26-000166
2026-05-29Filed 2026-06-02	THULIN INGE GDirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 1-for-1 F2 Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 Holdings include shares acquired in dividend reinvestment transactions. References: F1, F2, F3	A Award / grantPhantom Stock · Derivative	1,853.0997A	118.72	Direct	Form 4 ↗0000310158-26-000163
2026-05-29Filed 2026-06-02	Seidman Christine EDirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 1-for-1 F2 Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 Holdings include shares acquired in dividend reinvestment transactions. References: F1, F2, F3	A Award / grantPhantom Stock · Derivative	1,853.0997A	118.72	Direct	Form 4 ↗0000310158-26-000161
2026-05-29Filed 2026-06-02	RUSSO PATRICIA FDirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 1-for-1 F2 Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 Holdings include shares acquired in dividend reinvestment transactions. References: F1, F2, F3	A Award / grantPhantom Stock · Derivative	1,853.0997A	118.72	Direct	Form 4 ↗0000310158-26-000159
2026-05-29Filed 2026-06-02	Rothman PaulDirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 1-for-1 F2 Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 Holdings include shares acquired in dividend reinvestment transactions. References: F1, F2, F3	A Award / grantPhantom Stock · Derivative	1,853.0997A	118.72	Direct	Form 4 ↗0000310158-26-000157
2026-05-29Filed 2026-06-02	Mayo StephenDirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 1-for-1 F2 Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 Holdings include shares acquired in dividend reinvestment transactions. References: F1, F2, F3	A Award / grantPhantom Stock · Derivative	1,853.0997A	118.72	Direct	Form 4 ↗0000310158-26-000155
2026-05-29Filed 2026-06-02	LAVIZZO-MOUREY RISA JDirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 1-for-1 F2 Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 Holdings include shares acquired in dividend reinvestment transactions. References: F1, F2, F3	A Award / grantPhantom Stock · Derivative	1,853.0997A	118.72	Direct	Form 4 ↗0000310158-26-000153
2026-05-29Filed 2026-06-02	GLOCER THOMAS HDirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 1-for-1 F2 Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 Holdings include shares acquired in dividend reinvestment transactions. References: F1, F2, F3	A Award / grantPhantom Stock · Derivative	1,853.0997A	118.72	Direct	Form 4 ↗0000310158-26-000150

Imported instruments only. Joint owners do not multiply transactions. Amendments are separate filing rows, not additional trades. No aggregate trade totals are implied.